CALL FOR ABSTRACTS WILL OPEN AUGUST, 20.
This online abstract submission will close on October 8, 2025. No late abstracts will be accepted. Presenting authors will be notified of the Scientific Committee's decision regarding acceptance of their abstracts. Presenting authors must be registered to ICFSR25 by January 15, 2026 or their abstract will be discarded from the program.
Only abstracts submitted via the online system will be taken into account. Please do not send abstracts by email as they will not be considered.
Please note that abstracts submitted for an oral communication will automatically be considered for a poster presentation if not selected for an oral communication. Do not submit abstracts twice. Double submissions will be discarded from the system.
✅ I. GEROSCIENCE Clinical & preclinical trials
Focus: Randomized clinical and pre-clinical trials for healthy Longevity , Biology of aging, aging-related mechanisms, translational geroscience, and preventive strategies .
Included topics but not limited to:
- Clinical trials methods - target population, primary and secondary endpoints
- Geroscience: Senescent Cells – aging hallmarks, senolytics.
- Animal Models, Preclinical trials – mechanistic exploration of aging and frailty.
- Biomarkers and Imaging for geroscience & healthy longevity – when focused on aging processes (molecular, physiological).
- Drug Developments & preclinical clinical trials – novel agents targeting aging pathways.
- Multidomain and lifestyle interventions for healthy longevity
- GLP-1 agonists in Geroscience – metabolic aging, weight loss in aging.
- Longevity Clinics – translation of geroscience into clinical settings.
✅ II. INTRINSIC CAPACITY
Focus: WHO Intrinsic Capacity framework (mobility, vitality, cognition, psychological and sensory functions), its measurement, trajectory, and interventions.
Included topics:
- Clinical measures for Intrinsic Capacity
- Intrinsic Capacity Biomarkers
- Change of Intrinsic Capacity with age
- ICOPE – WHO program to implement IC as a clinical paradigm.
- ICOPE Clinical Implementation – real-world strategies and tools.
- Intrinsic capacity clinical trials – human trials using IC measures.
- Digital biomarkers for Intrinsic Capacity – technology for monitoring IC.
- Intervention studies to maintain or restore Intrinsic Capacity – including pharmacologic and non-pharmacologic.
- Imaging and Intrinsic Capacity – visual assessment of IC domains.
- Intrinsic Capacity Endpoints and Entry Criteria for RCTs – methodological innovation.
- Machine learning, AI tools for prediction, prevention and assistance in measuring IC
✅ III. FRAILTY
Focus: Clinical, functional, and public health dimensions of frailty, prevention strategies, trial outcomes, and policy implications.
Included topics:
- Frailty in Clinical Practice and Public Health – implementation, screening, service delivery.
- Cognitive Frailty – dual decline in physical and cognitive domains.
- Clinical Trials and Therapeutics – trials targeting frailty as an endpoint.
- Epidemiology – frailty prevalence, determinants, and outcomes.
- Osteoporosis & Frailty – musculoskeletal vulnerability.
- Vaccination, Frailty and Healthy Aging – frailty-related immune risk.
- Nutrition and Aging – when framed around frailty prevention/reversal.
- Drug Developments – drugs designed to reduce frailty burden.
- Machine learning, AI tools for prediction, prevention and assistance in frailty
- Frailty and resilience
✅ IV. SARCOPENIA
Focus: Muscle mass, strength, physical performance, functional decline, and its clinical management.
Included topics:
- Physical Exercise – resistance, multicomponent programs.
- Body Composition – muscle/fat quantification and clinical meaning.
- Biology of Frailty, Sarcopenia – molecular, cellular mechanisms of muscle loss.
- GLP-1 agonists in weight loss and sarcopenia – drug effects on muscle/fat balance.
- Nutrition and Aging – when aimed at muscle mass/preservation.
- Clinical Trials and Therapeutics – studies focused on sarcopenia treatment.
- Machine learning, AI tools for prediction, prevention and assistance in sarcopenia
✅ V. BIOTECH SHOWCASE SESSIONS
As part of a new initiative at ICFSR 2026, we are hosting Biotech Showcase Sessions — dynamic flash presentation slots where selected biotech companies will:
- Present their work in 3-minute / 3-slide lightning talks
- Engage in 2 minutes of live Q&A with moderators and attendees
- Gain expert feedback and attract the attention of investors and strategic partners
- Build high-value connections with leaders in frailty, sarcopenia, and intrinsic capacity research
These sessions will take place in the main ballroom during dedicated showcase times, ensuring maximum visibility and engagement.
DOWNLOAD OUR GUIDELINES
